INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy